1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuroblastoma Treatment Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Country/Region, 2017, 2022 & 2028
2.2 Neuroblastoma Treatment Drugs Segment by Type
2.2.1 Cyclophosphamide
2.2.2 Dinutuximab
2.2.3 Naxitamab
2.2.4 Doxorubicin Hydrochloride
2.2.5 Vincristine Sulfate
2.2.6 Other
2.3 Neuroblastoma Treatment Drugs Sales by Type
2.3.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Neuroblastoma Treatment Drugs Sale Price by Type (2017-2022)
2.4 Neuroblastoma Treatment Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Neuroblastoma Treatment Drugs Sales by Application
2.5.1 Global Neuroblastoma Treatment Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Neuroblastoma Treatment Drugs Sale Price by Application (2017-2022)
3 Global Neuroblastoma Treatment Drugs by Company
3.1 Global Neuroblastoma Treatment Drugs Breakdown Data by Company
3.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2020-2022)
3.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Neuroblastoma Treatment Drugs Revenue by Company (2020-2022)
3.2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Neuroblastoma Treatment Drugs Sale Price by Company
3.4 Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroblastoma Treatment Drugs Product Location Distribution
3.4.2 Players Neuroblastoma Treatment Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Neuroblastoma Treatment Drugs by Geographic Region
4.1 World Historic Neuroblastoma Treatment Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Geographic Region
4.2 World Historic Neuroblastoma Treatment Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Neuroblastoma Treatment Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Country/Region
4.3 Americas Neuroblastoma Treatment Drugs Sales Growth
4.4 APAC Neuroblastoma Treatment Drugs Sales Growth
4.5 Europe Neuroblastoma Treatment Drugs Sales Growth
4.6 Middle East & Africa Neuroblastoma Treatment Drugs Sales Growth
5 Americas
5.1 Americas Neuroblastoma Treatment Drugs Sales by Country
5.1.1 Americas Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
5.1.2 Americas Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
5.2 Americas Neuroblastoma Treatment Drugs Sales by Type
5.3 Americas Neuroblastoma Treatment Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroblastoma Treatment Drugs Sales by Region
6.1.1 APAC Neuroblastoma Treatment Drugs Sales by Region (2017-2022)
6.1.2 APAC Neuroblastoma Treatment Drugs Revenue by Region (2017-2022)
6.2 APAC Neuroblastoma Treatment Drugs Sales by Type
6.3 APAC Neuroblastoma Treatment Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neuroblastoma Treatment Drugs by Country
7.1.1 Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
7.1.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
7.2 Europe Neuroblastoma Treatment Drugs Sales by Type
7.3 Europe Neuroblastoma Treatment Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuroblastoma Treatment Drugs by Country
8.1.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type
8.3 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs
10.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
10.4 Industry Chain Structure of Neuroblastoma Treatment Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroblastoma Treatment Drugs Distributors
11.3 Neuroblastoma Treatment Drugs Customer
12 World Forecast Review for Neuroblastoma Treatment Drugs by Geographic Region
12.1 Global Neuroblastoma Treatment Drugs Market Size Forecast by Region
12.1.1 Global Neuroblastoma Treatment Drugs Forecast by Region (2023-2028)
12.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neuroblastoma Treatment Drugs Forecast by Type
12.7 Global Neuroblastoma Treatment Drugs Forecast by Application
13 Key Players Analysis
13.1 United Therapeutics
13.1.1 United Therapeutics Company Information
13.1.2 United Therapeutics Neuroblastoma Treatment Drugs Product Offered
13.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 United Therapeutics Main Business Overview
13.1.5 United Therapeutics Latest Developments
13.2 Y-mAbs Therapeutics
13.2.1 Y-mAbs Therapeutics Company Information
13.2.2 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offered
13.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Y-mAbs Therapeutics Main Business Overview
13.2.5 Y-mAbs Therapeutics Latest Developments
13.3 EUSA Pharma
13.3.1 EUSA Pharma Company Information
13.3.2 EUSA Pharma Neuroblastoma Treatment Drugs Product Offered
13.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 EUSA Pharma Main Business Overview
13.3.5 EUSA Pharma Latest Developments
13.4 ANI Pharmaceuticals
13.4.1 ANI Pharmaceuticals Company Information
13.4.2 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
13.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 ANI Pharmaceuticals Main Business Overview
13.4.5 ANI Pharmaceuticals Latest Developments
13.5 Baxter Healthcare
13.5.1 Baxter Healthcare Company Information
13.5.2 Baxter Healthcare Neuroblastoma Treatment Drugs Product Offered
13.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Baxter Healthcare Main Business Overview
13.5.5 Baxter Healthcare Latest Developments
13.6 Ingenus Pharmaceuticals
13.6.1 Ingenus Pharmaceuticals Company Information
13.6.2 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
13.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Ingenus Pharmaceuticals Main Business Overview
13.6.5 Ingenus Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Neuroblastoma Treatment Drugs Product Offered
13.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Hikma Pharmaceuticals
13.8.1 Hikma Pharmaceuticals Company Information
13.8.2 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
13.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Hikma Pharmaceuticals Main Business Overview
13.8.5 Hikma Pharmaceuticals Latest Developments
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Information
13.9.2 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
13.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Teva Pharmaceuticals Main Business Overview
13.9.5 Teva Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer